Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00813787
Recruitment Status : Unknown
Verified October 2014 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
First Posted : December 23, 2008
Last Update Posted : October 3, 2014
Information provided by (Responsible Party):
AHS Cancer Control Alberta

Brief Summary:
The purpose of this study is to see if a specialized imaging technique using MRI called multi-exponential T2 component analysis can reliably differentiate between normal brain and brain tumour.

Condition or disease

Detailed Description:
Existing methods of contouring tumours for radiation therapy involve manual interpretations of qualitative diagnostic images. These methods, being qualitative, do not offer a consistent and reproducible platform for contouring, making it difficult to evaluate the effects of contouring choices on treatment outcome. T2 component analysis in MRI has the potential to offer a quantitive basis for identifying tumor tissue- this potential is investigated in this pilot study.

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis
Study Start Date : February 2009
Estimated Primary Completion Date : April 2015
Estimated Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

A. glioma
A. glioma population
B. Normal brain
B. Normal brain

Primary Outcome Measures :
  1. T2 characteristics of glioma tissue versus normal [ Time Frame: Before radiotherapy treatment begins ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who agrees to take part in the study.

B. Any normal volunteer who agrees to take part in the study.


Inclusion Criteria:

  • Eighteen years of age or older
  • Clinical subjects must have not yet begun radiation therapy
  • Must have signed our study-specific consent form

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00813787

Contact: Keith Wachowicz, PhD (780) 989-4334

Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Study Chair: Keith Wachowicz, PhD AHS Cancer Control Alberta

Responsible Party: AHS Cancer Control Alberta Identifier: NCT00813787     History of Changes
Other Study ID Numbers: CNS-24534
First Posted: December 23, 2008    Key Record Dates
Last Update Posted: October 3, 2014
Last Verified: October 2014

Keywords provided by AHS Cancer Control Alberta:
Magnetic Resonance Imaging

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue